BMY Stock Recent News

The drugmaker's newest therapies are seeing unexpectedly strong sales growth. Its legacy drug portfolio, meanwhile, is still a solid cash cow.

Bristol-Myers Squibb Company (NYSE:BMY ) Q2 2024 Earnings Conference Call July 26, 2024 8:00 AM ET Company Participants Tim Power - Vice President, Head of Investor Relations Chris Boerner - Board Chair and Chief Executive Officer David Elkins - Executive Vice President and Chief Financial Officer Adam Lenkowsky - Executive Vice President, Chief Commercialization Officer Samit Hirawat - Executive Vice President, Chief Medical Officer, Global Drug Development Conference Call Participants Chris Schott - JPMorgan Luisa Hector - Berenberg Chris Shibutani - Goldman Sachs Tim Anderson - Wolfe Research Evan Seigerman - BMO Capital Markets Carter Gould - Barclays Seamus Fernandez - Guggenheim Securities Terence Flynn - Morgan Stanley Mohit Bansal - Wells Fargo David Risinger - Leerink Partners Steve Scala - TD Cowen Trung Huynh - UBS Matthew Phipps - William Blair Olivia Brayer - Cantor Fitzgerald Steve Chesney - Redburn Atlantic James Shin - Deutsche Bank Kripa Devarakonda - Truist Securities

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining over 100 points on Friday.

PCE/Core PCE Inflation In Line With Estimates in June.

Bristol-Myers Squibb (BMY) shares climbed Friday after the company beat expectations with its second-quarter results and raised its full-year guidance.

While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Bristol Myers Squibb (BMY) came out with quarterly earnings of $2.07 per share, beating the Zacks Consensus Estimate of $1.64 per share. This compares to earnings of $1.75 per share a year ago.

Global sales of Eliquis, a drug used to reduce the risk of stroke and blood clots, increase 7% in the second quarter from a year earlier.

Drugmaker Bristol Myers Squibb posted better-than-expected second-quarter results, driven by growth from new products like anemia treatment Reblozyl and heart drug Camzyos as well as from its top-seller, blood thinner Eliquis.

Bristol Myers Squibb reported second-quarter earnings and revenue that topped expectations and raised its full-year guidance. Revenue growth was primarily driven by the company's blockbuster blood thinner Eliquis and a portfolio of drugs it expects to help it deliver long-term growth.